R&D News | pharmaphorum

News

Can Pfizer, Sangamo energise haemophilia A gene therapy?

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow.

News

Biogen, Sage drug for essential tremor flunks mid-stage test

Biogen's $3 billion alliance with Sage Therapeutics has suffered another setback after their drug for essential tremor failed to move the needle in a phase 2 study.

News

Asarina folds as it ends search for Tourette's drug partner

The directors of Asarina Pharma have abandoned a search for a partner for Tourette's syndrome treatment sepranolone, saying they have no choice but to liquidate the company.

News

MSD stakes claim to RSV prevention market for infants

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro

News

Agilent builds its CDMO arm with $925m Biovectra buy

Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and ac

News

GSK's Dovato matches rival Biktarvy with less weight gain

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain.

Can Pfizer, Sangamo energise haemophilia A gene therapy?

Biogen, Sage drug for essential tremor flunks mid-stage test

Asarina folds as it ends search for Tourette's drug partner

MSD stakes claim to RSV prevention market for infants

Agilent builds its CDMO arm with $925m Biovectra buy

GSK's Dovato matches rival Biktarvy with less weight gain

Novartis CEO joins board of "responsible" AI firm Anthropic

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks